856253-13-9

Upstream product

• 4885-02-3 Dichloromethyl methyl ether 
• 51345-97-2 4-Bromo-2-tert-butyl-5-methyl-phenol 
• 50-00-0 formaldehyd 
• 88-60-8 2-tert-Butyl-5-methylphenol 

Downstream Products

• 856253-14-0 3-bromo-5-tert-butyl-6-isopropoxy-2-methyl-benzaldehyde 
• 1433065-16-7 C₁₈H₂₇BrO₄ 
• 1433065-22-5 C₁₈H₂₇IO₃ 
• 1433065-10-1 C₁₈H₂₅BrO₄ 

Relevant academic research and scientific papers

Asymmetric induction via short-lived chiral enolates with a chiral C-O axis

A novel method has been developed for the asymmetric cyclization of alkyl aryl ethers. The reactions were assumed to proceed via short-lived chiral enolate intermediates with a chiral C-O axis to give cyclic ethers with tetrasubstituted carbon in up to 99% ee. The half-life of racemization of the chiral enolate intermediate was roughly estimated to be ～1 s at -78 C.

METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B

The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.

COMPOUNDS HAVING SELECTIVE CYTOCHROME P450RAI-1 OR SELECTIVE CYTOCHROME P450RAI-2 INHIBITORY ACTIVITY AND METHODS OF OBTAINING THE SAME

Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.